Antibody-directed superantigen-mediated T-cell killing of myeloid leukaemic cell line cells

European Journal of Haematology

Volumn 60, Issue 4, 1998, Pages 233-239

  Gidlöf, Cecilia ^a   Carlson, Barbro ^a,b   Dohlsten, Mikael ^c,d   Tötterman, Thomas H ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c Pharmacia & Upjohn AB   (Sweden)

^d LUND UNIVERSITY   (Sweden)

Author keywords

CD13; CD33; Cytotoxic T cells; Monoclonal antibody; Myeloid leukaemic cell line cells; Superantigen

Indexed keywords

CD33 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; MICROSOMAL AMINOPEPTIDASE; MONOCLONAL ANTIBODY; STAPHYLOCOCCUS ENTEROTOXIN; SUPERANTIGEN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIGEN ANTIBODY COMPLEX; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN HL 60; CHRONIC MYELOID LEUKEMIA; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN CELL; POINT MUTATION; PRIORITY JOURNAL; STAPHYLOCOCCUS; TARGET CELL;

EID: 0031968167     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.1998.tb01029.x     Document Type: Article

References (42)

1. STASI R, VENDITTI A, DEL POETA G, et al. High-dose chemotherapy in adult acute myeloid leukemia: rationale and results. Leuk Res 1996: 20: 535-549.
2. MARTINEZ-CLIMENT JA, LANE NJ, RUBIN CM, et al. Clinical and prognostic significance of chromosomal abnormalities in childhood acute myeloid leukemia de novo. Leukemia 1995: 9: 95-101.
3. CORTES JE, TALPAZ M, KANTARJIAN H. Chronic myelogenous leukemia: a review. Am J Med 1996: 100: 555-570.
4. DILLMAN RO. Antibodies as cytotoxic therapy. J Clin Oncol 1994: 12: 1497-1515.
5. ROY DC, GRIFFIN JD, BELVIN M, BLATTLER WA, LAMBERT JM, RITZ J. Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells. Blood 1991: 77: 2404-2412.
6. JURCIC JG, CARON PC, MILLER JR WH, et al. Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans Retinoic acid and anti-CD33 monoclonal antibody M195. Leukemia 1995: 9: 244-248.
7. SCHWARTZ MA, LOVETT DR, REDNER A, et al. Doseescalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias. J Clin Oncol 1993: 11: 294-303.
8. SCHEINBERG DA, LOVETT D, DIVGI CR, et al. A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol 1991: 9: 478-490.
9. GOTTLIEB DJ, BRENNER MK, HESLOP HE, et al. A Phase I trial of recombinant interleukin-2 following high dose chemoradiotherapy for haematological malignancy: applicability to the elimination of minimal residual disease. Br J Cancer 1989: 60: 610-615.
10. GOTTLIEB DJ, PRENTICE HG, HESLOP HE, et al. Effects of recombinant interleukin-2 administration on cytotoxic effector function following intensive chemoradiotherapy. Blood 1989: 74: 2335-2342.
11. ROSENBERG SA, LOTZE MT, MULE JJ. New approaches to the immunotherapy of cancer using interleukin-2. Ann Intern Med 1988: 108: 853-864.
12. BLAISE D, OLIVE D, STOPPA AM, et al. Hematologic and immunologic effects of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 1990: 76: 1092-1097.
13. ABRAHMSÉN L, DOHLSTEN M, SEGRF́N S, BJÖRK P, JONSSON E, LLAND T. Characterization of two distinct MHC class II binding sites in the superantigen staphylococcal enterotoxin A. EMBO 1995: 14: 2978-2986.
14. MARRACK P, KAPPLER J. The staphylococcal enterotoxins and their relatives. Science 1990: 248: 705-711.
15. HERMAN A, LABRECQUE N, THIOBODEAU J, MARRACK P, KAPPLER JW, SÉKALY R-P. Identification of the staphylococcal enterotoxin A superantigen binding site in the β1 domain of the human histocompatibility antigen HLA-DR. Proc Natl Acad Sci 1991: 88: 9954-9958.
16. DOHLSTEN M, ABRAHMSEN L, BJÖRK P, et al. Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T cell based tumor therapy. Proc Natl Acad Sci USA 1994: 91: 8945-8949.
17. - T helper cells differing in kinetics and capacities to produce interleukin 2 and interferon-gamma can be defined by the Leu-18 and UCHL1 monoclonal antibodies. Eur J Immunol 1988: 18: 1173-1178.
18. FISCHER H, DOHLSTEN M, ANDERSSON U, et al. Production of TNF-α and TNF-β by staphylococcal enterotoxin A activated human T cells. J Immunol 1990: 144: 4663-4669.
19. DOHLSTEN M, LANDO PA, HEDLUND G, TROWSDALE J, KALLAND T. Targeting of human cytotoxic T lymphocytes to MHC class II-expressing cells by staphylococcal enterotoxins. Immunology 1990: 71: 96-100.
20. WALLGREN A-C, FESTIN R, GIDLÖF C, DOHLSTEN M, KALLAND T, TÖTTERMAN TH. Efficient killing of chronic B-lymphocytic leukemia cells by superantigen-directed T cells. Blood 1993: 82: 1230-1238.
21. TAKETAZU F, KUBOTA K, KAJIGAYA S, et al. Clonal growth of human acute myeloid leukemia cells (ML-1 and HL-60) in serum-free agar medium. Cancer Res 1984: 44: 531-535.
22. SUZUKI K, YAMAKAWA Y, MATSUO Y, KAMIYA T, MINOWADA J, MIZUNO S. Isolation and amino acid sequence of a chemotaetic protein, LECT/interleukin 8, from a human myeloid leukamia cell line, ML-1. Immunol Lett 1993: 36: 71-81.
23. HASKOVEC C, LEMEZ P, NEUWIRTOVA R, WILHELM J, JAROLIM P. Differentiation of human myeloid leukemia cell line ML-1 induced by retinoic acid and 1,25-dihydroxyvitamin D3. Neoplasma 1990: 37: 565-572.
24. GALLAGHER R, COLLINS S, TRUJILLO J, et al. Characterization of the continous, differentiating myeloid cell line (HL-60) from a patient with acute promyelocytic leukemia. Blood 1979: 54: 713-733.
25. HARRIS P, RALPH P. Human leukemic models of myelomonocytic development: a review of the HL-60 and U937 cell lines. J Leuk Biol 1985: 37: 407-422.
26. TSUCHIYA S, YAMABE M, YAMAGUCHI Y, KOBAYASHI Y, KONNO T, TADA K. Establishment and characterization of a human acute monocytic leukemia cell line (THP-1). Int J Cancer 1980: 26: 171-176.
27. ZIEGLER-HEITBROCK HWL, THIEL E, FÜTTERER A, HERZOG V, WIRTZ A, RIETHMÜLLER G. Establishment of a human cell line (Mono-Mac-6) with characteristics of mature monocytes. Int J Cancer 1988: 41: 456-461.
28. MACLEOD RAF, VOGES M, DREXLER HG. Mono Mac 6: a mature monoblastic cell line with t(9;11)(p21:q23) (letter). Blood 1993: 82: 3221-3222.
29. KOEFFLER HP, GOLDE DW. Acute myelogenous leukemia: a human cell line responsive to colony-stimulating activity. Science 1978: 200: 1153-1154.
30. MARTIN P, PAPAYANNOPOULOU T. HEL cells: a new human erythroleukemia cell line with spontaneous and induced globin expression. Science 1982: 216: 1233-1235.
31. LOZZIO CB, LOZZIO BB. Human chronic myelogenous leukemia cell-line with positive Philadelphia chromosome. Blood 1975: 45: 321-334.
32. RASKIND WH, DISTECHE CM, KEATING A, SINGER JW. Correlation between cytogenetic and molecular findings in human chronic myelogenous leukemia lines EM-2 and EM-3. Cancer Genet Cytogenet 1987: 25: 271-284.
33. BERAN M, PISA P, O'BRIEN S, et al. Biological properties and growth in SCID mice of a new myelogenous leukemia cell line (KBM-5) derived from chronic myelogenous leukemia cells in the blastic phase. Cancer Res 1993: 53: 3603-3610.
34. BERAN M, ANDERSON BS, KELLEHER P, WHALEN K, MCCREDIE K, GUTTERMAN J. Diversity of the effect of recombinant tumor necrosis factors a and b on human myelogenous leukemia cell lines. Blood 1987: 69: 721-726.
35. ANDERSSON BS, BERAN M, PATHAK S, GOODACRE A, BARLOGIE B, MCCREDIE KB. Ph-positive chronic myeloid leukemia with near-haploid conversion in vivo and establishment of a continuously growing cell line with similar cytogenetic pattern. Cancer Genet Cytogenet 1987: 24: 335-343.
36. GIDLÖF C, DOHLSTEN M, KALLAND T, TÖTTERMAN TH. Antibodies are capable of directing superantigen-mediated T cell killing of chronic B lymphocytic leukemia cells. Leukemia 1995: 9: 1534-1542.
37. DOHLSTEN M, LANDO PA, BJÖRK P, et al. Immunotherapy of human colon cancer by antibody-targeted superantigens. Cancer Immunol Immunother 1995: 41: 162-168.
38. GIDLÖF C, DOHLSTEN M, LANDO P, KALLAND T, SUNDSTRÖM C, TÖTTERMAN TH. A superantigen-antibody fusion protein for T cell immunotherapy of human B-lineage malignancies. Blood 1997: 89: 2089-2097.
39. BARCLAY AN, BIRKELAND ML, BROWN MH, eds. The Leukocyte Antigen Facts Book (1st edn). London: Academic Press Ltd, 1993.
40. SIMMONS D, SEED B. Isolation of a cDNA encoding CD33, a differentiation antigen of myeloid progenitor cells. J Immunol 1988: 141: 2797-2800.
41. CARON PC, CO MS, BULL MK, AVDALOVIC NM, QUEEN C, SCHEINBERG DA. Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res 1992: 52: 6761-6767.
42. CARON PC, LAI LT, SCHEINBERG DA. Interleukin-2 enhancement of cytotoxicity by humanized monoclonal antibody M195 (anti-CD33) in myelogenous leukemia. Clin Cancer Res 1995: 1: 63-70.